hCAI II-IN-4 (compound 6d) is a powerful inhibitor of both hCA I and hCA II enzymes, with Ki values of 16.95 nM and 15.22 nM, respectively. It demonstrates inhibitory activity against hCA IX with a Ki value of 27.04 nM. Additionally, hCAI II-IN-4 exhibits anti-hypoxia properties while maintaining low toxicity. This compound is suitable for investigating acute mountain sickness (AMS) in research studies [1].
KCN1, a novel synthetic sulfonamide, is a HIF pathway inhibitor with potential anticancer activity in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. KCN1 specifically inhibited HIF reporter gene activity in several glioma cell lines at the nanomolar level. KCN1 also downregulated transcription of endogenous HIF-1 target genes, such as VEGF, Glut-1, and carbonic anhydrase 9, in a hypoxia-responsive element (HRE)-dependent manner. KCN1 potently inhibited the growth of subcutaneous malignant glioma tumor xenografts with minimal adverse effects on the host.